Highest-materiality recent filing
Xencor reports Q1 net loss $128.9M ($1.71/shr); revenue down to $4.5M from $32.7M
Q1 2026 revenue $4.5M (vs $32.7M Q1 2025), including a $6.6M one-time reduction from Alexion royalty dispute.
XmAb942 achieved 74.1-day half-life; supports single SC dose every 12 weeks during maintenance.
Alexion refuses further US Ultomiris royalties; Xencor disputes, cuts revenue forecast
Alexion informed Xencor it will not pay additional US royalties on Ultomiris and will cease future US payments.
Xencor Q4 net loss narrows to $6.7M; XmAb819 dose expansion advances; Xtend royalty upside $100-120M
Q4 revenue $28.2M (down 47% YoY), full year $125.6M (up 14%). Net loss $6.7M ($0.09/sh) vs $45.6M prior-year Q4.
Xencor narrows Q3 net loss to $6M; advances key bispecific antibodies toward pivotal studies
Net loss $6.0M ($0.08 per share) vs $46.3M loss ($0.72) in Q3 2024; revenue $21.0M, up from $17.8M.
Xencor reports 25% ORR for XmAb819 in ccRCC Phase 1; dose-expansion cohort selected
XmAb819 (ENPP3 x CD3) Phase 1: 25% ORR (5/20 PRs) and 70% DCR in target dose range in heavily pre-treated ccRCC.
Xencor Q2 2025 revenue $43.6M, net loss $30.8M; Incyte milestone $25M
Revenue $43.6M (up from $23.9M Q2 2024); net loss $30.8M ($0.41/share) vs $67.3M ($1.09) prior year.
Xencor Q1 net loss narrows to $48.4M; CDO Valente resigns, Phase 2b UC study on track
Q1 revenue $32.7M (up from $16.0M YoY); net loss $48.4M (-$0.66 EPS) versus $73.4M (-$1.20 EPS) prior year.
Xencor reports positive interim Phase 1 results for XmAb942; half-life >71 days
XmAb942 well tolerated; no serious AEs, no discontinuations.
Xencor dismisses auditor RSM, appoints KPMG after material weaknesses and restatement
Dismissed RSM on Feb 27, 2025; engaged KPMG effective March 3, 2025.
Xencor dismisses RSM as auditor over material weaknesses; appoints KPMG
RSM dismissed Feb 27, 2025; KPMG appointed effective Mar 3, 2025.
Xencor Q4 net loss widens to $45.6M; full-year revenue falls 37% to $110.5M
Q4 revenue $52.8M (+3.5% YoY) driven by milestone payments; full-year revenue $110.5M vs $174.6M.
Xencor restates FY2023 and Q1-Q3 2024 results; errors in royalty accounting and tax
Royalty transaction with OMERS Life Sciences misclassified as deferred income instead of debt; impacted balance sheet by ~$168.5M debt understatement.
Xencor Q3 net loss $45.1M ($0.71 EPS), revenue down 82% YoY; cash $754M
Net loss of $45.1M ($0.71 diluted EPS) vs net loss of $24.3M ($0.40) in Q3 2023.
Xencor prices $175M public offering of common stock and pre-funded warrants
Offering of 6,635,112 shares at $18.00/share and pre-funded warrants for 3,088,888 shares at $17.99 each.
Xencor unveils autoimmune pipeline, reports initial XmAb819 RECIST responses in ccRCC
XmAb942 (anti-TL1A) Phase 1 healthy volunteer study starts Q4 2024; interim data in H1 2025.
Xencor Q2 net loss widens to $66M; revenue falls 63% YoY to $17M
Net loss $66.0M ($1.07 diluted EPS) vs $22.0M ($0.37) in Q2 2023; net loss $134M YTD.
Xencor Regains Exclusive Worldwide Rights to Plamotamab After Janssen Termination
Xencor regains worldwide rights to plamotamab, a CD20 x CD3 bispecific T-cell engager, after Janssen terminates its rights.
Xencor Q1 2024 net loss $68.0M ($1.11/share); revenue down to $12.8M from $19.0M
Net loss widened to $68.0M from $60.8M YoY; diluted EPS -$1.11 vs -$1.02.
On May 5, 2025, Nancy Valente, Executive Vice President and Chief Development Officer, notified the Company of her intention to resign from the Company effective June 6, 2025, and remain as a senior advisor.
Todd Simpson was appointed to serve as a new member of the Board of Directors (the “Board”) of Xencor, Inc. (the “Company”).
On September 30, 2024 Dagmar Rosa-Bjorkeson provided notice to the board of directors (the “Board”) of Xencor, Inc. (the “Company”) of her intent not to stand for reelection to the Board at the Company’s 2025 Annual Meeting of Stockholders.
Max materiality 0.90 · Median 0.65 · Most common event other_material